Organon (OGN) Non-Current Deferred Tax Liability (2020 - 2026)
Organon (OGN) posted quarterly Non-Current Deferred Tax Liability of $56.0 million for Q1 2026, down 18.84% year-over-year from $69.0 million in Q1 2025, and down 1.75% on a QoQ basis from $57.0 million in Q4 2025.
Organon (OGN) Non-Current Deferred Tax Liability (2020 - 2026) Analysis & Trends
Organon (OGN) has reported Non-Current Deferred Tax Liability for 7 consecutive years, with $56.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability fell 18.84% year-over-year to $56.0 million; the TTM figure through Mar 2026 stood at $56.0 million (down 18.84% YoY), while the FY2025 annual figure was $57.0 million, down 65.24% from the prior year.
- Non-Current Deferred Tax Liability came in at $56.0 million for Q1 2026 at Organon, down from $57.0 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $164.0 million in Q4 2024, with the low at $2.0 million in Q1 2022.
- Average Non-Current Deferred Tax Liability over 5 years is $51.5 million, with a median of $47.0 million recorded in 2023.
- Across the five-year window, Non-Current Deferred Tax Liability slumped 98.4% in 2022 and surged 1400.0% in 2023, its largest moves.
- Year by year, Non-Current Deferred Tax Liability stood at $19.0 million in 2022, then jumped by 147.37% to $47.0 million in 2023, then soared by 248.94% to $164.0 million in 2024, then slumped by 65.24% to $57.0 million in 2025, then dropped by 1.75% to $56.0 million in 2026.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $56.0 million, $57.0 million, and $62.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.00 Mn |
| Mar 31, 2026 | 56.00 Mn |
| Dec 31, 2025 | 57.00 Mn |
| Dec 31, 2025 | 57.00 Mn |
| Sep 30, 2025 | 62.00 Mn |
| Sep 30, 2025 | 62.00 Mn |
| Jun 30, 2025 | 69.00 Mn |
| Jun 30, 2025 | 69.00 Mn |
| Mar 31, 2025 | 69.00 Mn |
| Mar 31, 2025 | 69.00 Mn |
| Dec 31, 2024 | 164.00 Mn |
| Dec 31, 2024 | 164.00 Mn |
| Sep 30, 2024 | 56.00 Mn |
| Sep 30, 2024 | 56.00 Mn |
| Jun 30, 2024 | 60.00 Mn |
| Jun 30, 2024 | 60.00 Mn |
| Mar 31, 2024 | 44.00 Mn |
| Mar 31, 2024 | 44.00 Mn |
| Dec 31, 2023 | 47.00 Mn |
| Dec 31, 2023 | 47.00 Mn |